NEKTAR THERAPEUTICS
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
NKTR$37.78-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
|---|---|
| Reports of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 54 |
| Consolidated Balance Sheets at December 31, 2023 and 2022 | 57 |
| Consolidated Statements of Operations for each of the three years in the period ended December 31, 2023 | 58 |
| Consolidated Statements of Comprehensive Loss for each of the three years in the period ended December 31, 2023 | 59 |
| Consolidated Statements of Stockholders’ Equity for each of the three years in the period ended December 31, 2023 | 60 |
| Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2023 | 61 |
| Notes to Consolidated Financial Statements | 62 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.